

## To begin with...





















Beat AML® Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to identify each patient's cancer-driving genetic mutations, and then matches patients to the targeted treatment.





- Investigational Multi-Cancer Early Detection Blood Test
- 6600 participants enrolled









FDA approved avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a plateletderived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.









"This award will make it possible for us to reach out to veterans throughout Oregon and Southwest Washington to offer genetic testing and sequencing for all patients with metastatic prostate cancer."



Julie Graff, M.D









Flavio Rocha, M.D., F.A.C.S.



